ValGenesis Inc., a Santa Clara, California-based leader in digital validation lifecycle management, announced on July 22, 2025, a strategic financing round of up to $16 million from Bridge Bank’s Innovation Banking Group, with support from existing investor Morgan Stanley Expansion Capital. The funding will accelerate ValGenesis’ global expansion, strategic hiring, and innovation in AI-powered validation solutions, including the recently launched ValGenesis Smart GxP™, in the $5.6 billion life sciences software market.
Announced July 22, 2025: $16M financing from Bridge Bank, backed by Morgan Stanley Expansion Capital.
Funds to support global expansion, hiring, and AI-driven validation innovation.
ValGenesis Smart GxP™, an AI-enabled platform, unifies validation and process management.
Trusted by 30 of the top 50 global life sciences companies, with 4 issued patents.
Life sciences software market valued at $5.6B, projected to reach $11.2B by 2030.
Follows $24M investment from Morgan Stanley in 2021 for digital validation.
The $16 million financing will fuel ValGenesis’ expansion across North America, Europe, and Asia-Pacific, alongside investments in regional partnerships and customer success initiatives. “This financing reflects the strong confidence that Bridge Bank and Morgan Stanley Expansion Capital have in our vision, innovation, and execution,” said Dr. Siva Samy, CEO and Chief Product Strategist. The funds will enhance ValGenesis Smart GxP™, the first AI-enabled platform for unified validation and process lifecycle management, driving compliance and efficiency for pharmaceutical, biotech, and medical device companies.
Founded in 2005, ValGenesis pioneered the first 100% paperless validation lifecycle management system (VLMS), earning the 2005 PDA New Innovative Technology Award. Trusted by 30 of the world’s top 50 life sciences companies, its cloud-based platform ensures FDA 21 CFR Part 11 and EU Annex 11 compliance, reducing validation time by up to 50% and costs by 30%, per client data. The Smart GxP™ platform integrates AI to streamline risk-based validation, competing with Veeva Systems and MasterControl in a market projected to grow from $5.6 billion to $11.2 billion by 2030.
“Bridge Bank is honored to serve as the banking partner for ValGenesis, an innovation-driven company leading the way in digitalizing validation,” said Peter Haman, market director at Bridge Bank’s Innovation Banking Group. Melissa Daniels, Managing Director at Morgan Stanley Expansion Capital, added, “ValGenesis has consistently delivered impressive double-digit growth and carved out clear market leadership.” Morgan Stanley’s prior $24M investment in 2021 supported ValGenesis’ global customer base growth, now serving over 500 clients.
The life sciences industry faces increasing regulatory complexity, with 68% of companies citing compliance as a top challenge, per 2025 industry reports. ValGenesis’ AI-driven solutions address this, with Smart GxP™ enabling 40% faster process automation, per Scigeniq’s implementation data. Posts on X, such as @AiThority and @raisingfi, reflect enthusiasm for the financing, highlighting ValGenesis’ role in AI-driven transformation. Competitors like Sware and ProcellaRX are also innovating, but ValGenesis’ 4 patents and established client base give it a competitive edge.
ValGenesis’ $16 million financing, backed by Bridge Bank and Morgan Stanley, positions it to lead AI-driven digital validation, scaling globally to meet the life sciences industry’s demand for compliance and efficiency.
ValGenesis is the creator of ValGenesis Smart GxP, the life sciences industry’s first fully integrated, cloud-based, AI-enabled platform for end-to-end product lifecycle digitalization. Trusted by 30 of the world’s top 50 life sciences companies, our platform unifies intelligent, risk-based validation and process automation in a connected ecosystem—streamlining operations, driving compliance, and reducing risk. Purpose-built for life sciences, ValGenesis empowers global organizations to improve quality of life by accelerating the delivery of consistent, safer products.
Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. Morgan Stanley Expansion Capital targets growth equity and credit investments within technology, healthcare, consumer, digital media and other high-growth sectors. For over three decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 200 companies, leveraging the global brand and network of Morgan Stanley.
Bridge Bank, a division of Western Alliance Bank, Member FDIC, delivers relationship banking that puts clients at the center of everything. Founded in 2001 in Silicon Valley, Bridge Bank offers a full spectrum of tailored commercial banking solutions with specialized expertise focused on life sciences and technology and innovation companies at every stage in their life cycle, from startup to IPO and beyond. With offices in major tech hubs across the country, Bridge Bank delivers the reach, resources and market expertise that make a difference for its clients. Bridge Bank also serves the private equity and venture capital communities by providing banking solutions for portfolio companies and funds, plus banking solutions for small to mid-size businesses in the Bay Area. Bridge Bank is part of Western Alliance Bancorporation, which has more than $80 billion in assets. Major accolades include being ranked as a top U.S. bank in 2024 by American Banker and Bank Director.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.